RNXT|RenovoRx Inc|Price:0.959|Chg%:+0.093
RenovoRx, Inc. is a clinical and commercial biopharmaceutical company focused on oncology. Their primary product, RenovoCath, is a local drug delivery device, and they are evaluating a novel Phase III drug-device combination (intra-arterial gemcitabine, IAG) for pancreatic cancer. The article provides company details, executive …